Form 4: Director Sells Beta Bionics Shares Under 10b5-1 Plan

Beta Bionics Director Maria Palasis sold 1,406 shares of common stock for approximately $38,000 under a pre-arranged 10b5-1 trading plan.

Summary

• Maria Palasis, a Director of Beta Bionics, Inc. (BBNX), reported the sale of 1,406 shares of common stock.
• The sales occurred on October 31, 2025, pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025.
• One transaction involved 1,287 shares sold at a weighted average price of $26.8588, with prices ranging from $26.27 to $27.22.
• A second transaction involved 119 shares sold at a weighted average price of $27.4502, with prices ranging from $27.32 to $27.57.
• Following these transactions, Maria Palasis beneficially owns 9,841 shares of Beta Bionics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale under a 10b5-1 plan, which is generally not interpreted as a strong positive or negative signal regarding the company's future performance.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new, non-public information, which generally reduces concerns about insider selling.

Negatives

• A director's sale of shares reduces their direct ownership stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general perception of insider selling.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transaction reports (Form 4s) are routine filings for publicly traded companies, detailing changes in beneficial ownership by directors, officers, and significant shareholders. Sales under Rule 10b5-1 plans are common for personal financial planning and diversification.

Related Party Transactions

• The reported transactions involve a director of Beta Bionics, Inc. selling company stock, which is considered an insider transaction.

Stakeholder Impact

• Shareholders: A minor reduction in director ownership, but the pre-planned nature of the sale under a 10b5-1 plan mitigates concerns about the underlying health or prospects of the company.

Key Dates

Recommendation

The filing reports a routine, pre-planned sale of shares by a director under a Rule 10b5-1 plan. This type of transaction is common for diversification or liquidity purposes and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation.

Keywords

Beta Bionics, BBNX, Form 4, insider trading, stock sale, director, 10b5-1 plan